Moreover, downregulation of miR-193a-3p in IBD is related with the promotion of colitis-associated colorectal cancer [42,69] acting on the target mRNAs of the Interleukin-17 receptor D (IL-17RD) and the plasminogen activator urokinase (PLAU). Here, IL17RD is linked to inflammatory bowel disease.